30 Years of Genetics: Understanding BRCA and HRD in ovarian cancer

We will look at the discovery of BRCA1 and BRCA2 gene mutations, and how genetic testing became a key part of ovarian cancer care. Learn about homologous recombination deficiency (HRD) testing and how it’s helping guide treatment decisions. We will also introduce the Genetic Adviser platform – a new digital tool designed to empower patients and support them through the genetic testing process. Finally, a previvor advocate will share their personal experience, highlighting how genetics influenced their care and informed decisions about prevention and family planning.